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Introduction
Multidrug resistance (MDR) is a major problem in 
anticancer therapy and approximately 70-90% of patients 
do not respond to initial chemotherapy.1 Mechanisms of 
MDR including reduced drug uptake, active drug efflux by 
transporters of ATP-binding cassette (ABC) superfamily, 
decreased intracellular drug concentration, altered cell 
cycle checkpoints, and induced expression of genes 
for impairing apoptotic pathways of cell death are well 
studied.2,3 Nevertheless the problem of MDR reversion 
in cancer still remains. Thus, the chemical development 
of ABC transporter inhibitors was found to increase the 
toxicity associated with chemotherapy.4
Unique properties of C60 fullerene nanoparticles with 
the size of 10-100 nm distinguish them from other cancer 
therapeutics; they are non-toxic for normal cells,5,6 can 
bypass traditional drug resistance mechanisms,7,8 have 
therapeutic properties themselves as photosensitizers in 
photodynamic therapy (PDT),9-11 and enable combinatory 
treatment with anticancer drugs.12,13
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Abstract
Introduction: C60 fullerene has received great attention 
as a candidate for biomedical applications. Due to unique 
structure and properties, C60 fullerene nanoparticles are 
supposed to be useful in drug delivery, photodynamic 
therapy (PDT) of cancer, and reversion of tumor cells’ 
multidrug resistance. The aim of this study was to 
elucidate the possible molecular mechanisms involved 
in photoexcited C60 fullerene-dependent enhancement 
of cisplatin toxicity against leukemic cells resistant to 
cisplatin.
Methods: Stable homogeneous pristine C60 fullerene  queous colloid solution (10
-4 М, purity 99.5%) 
was used in the study. The photoactivation of C60 fullerene accumulated by L1210R cells was done 
by irradiation in microplates with light-emitting diode lamp (420-700 nm light, 100 mW·cm-2). 
Cells were further incubated with the addition of Cis-Pt to a final concentration of 1 μg/mL. 
Activation of p38 MAPK was visualized by Western blot analysis. Flow cytometry was used for 
the estimation of cells distribution on cell cycle. Mitochondrial membrane potential (Δψm) was 
estimated with the use of fluorescent potential-sensitive probe TMRE (Tetramethylrhodamine 
Ethyl Ester). 
Results: Cis-Pt applied alone at 1 μg/mL concentration failed to affect mitochondrial membrane 
potential in L1210R cells or cell cycle distribution as compared with untreated cells. Activation of 
ROS-sensitive proapoptotic p38 kinase and enhanced content of cells in subG1 phase were detected 
after irradiation of L1210R cells treated with 10-5M C60 fullerene. Combined treatment with 
photoexcited C60 fullerene and Cis-Pt was followed by the dissipation of Δψm at early-term period, 
blockage of cell transition into S phase, and considerable accumulation of cells in proapoptotic 
subG1 phase at prolonged incubation.
Conclusion: The effect of the synergic cytotoxic activity of both agents allowed to suppose that 
photoexcited C60 fullerene promoted Cis-Pt accumulation in leukemic cells resistant to Cis-Pt. The 
data obtained could be useful for the development of new approaches to overcome drug-resistance 
of leukemic cells. 
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and after toluene evaporation, C60 fullerene was transferred 
to the water phase followed by prolonged ultrasound 
sonication. An aqueous colloid solution of C60 fullerene 
(concentration 10-4 М, purity 99.5%) was highly stable for 
12 months when stored at room temperature.24 The average 
hydrodynamic diameter of C60 fullerene nanoparticles 
was 50 nm, and no changes in their size were detected in 
RPMI-1640 medium containing 5% FBS.25
Cell culture 
The murine cancer cell line of leukemic origin resistant to 
cisplatin L1210R was obtained from the Bank of Cell Lines 
from Human and Animal Tissues, R. E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobiology, 
NAS of Ukraine (Kyiv, Ukraine). Cells were incubated 
in RPMI 1640 medium supplemented with 10% FBS, 50 
μg·mL-1 penicillin and 100 μg·mL-1 streptomycin at 37°C 
in a humidified atmosphere with 5% CO2.
Photodynamic treatment
Cells were incubated for 2 hours with or without 10-5 М C60 
fullerene in a medium described above. Photoactivation of 
accumulated C60 fullerene was done by probes irradiation 
in microplates with light-emitting diode lamp (420-700 
nm light, irradiance 100mW·cm-2). Cells were further 
incubated for an indicated time period without or with the 
addition of cisplatin to a final concentration of 1 μg/mL in 
the incubation medium.
Immunoblot analysis
Cells were washed with PBS and lysed with ice-cold 
lysis buffer containing protease inhibitor. Cell lysates 
were centrifuged (14 000 g, 15 minutes) and 30 μg 
of cell lysate protein was loaded onto a gradient 8%-
15% SDS-polyacrylamide gel. After electrophoresis, 
the proteins were transferred onto polyvinylidene 
difluoride membrane26 and incubated overnight at 
4°C with monoclonal antibody against phospho-p38 
kinase (dilution 1:1000). The membranes were washed 
and incubated for 1 hour with anti-rabbit peroxidase-
linked secondary antibody. Immunoreactive bands were 
visualized by enhanced chemiluminescence plus western 
blotting detection system (Amersham, USA). Then, 
the membranes were incubated with antibodies against 
β-actin to provide the loading control. Finally, protein 
concentration was determined using DC Protein Assay kit 
(Bio-Rad, USA).
Cell cycle analysis
For cell cycle analysis, cells (1x106) were resuspended 
in 0.1 mL PBS (pH 7.4), fixed by adding 0.9 mL of 90% 
ethanol at -20°C overnight and centrifuged at 13000 g for 
1 minute. The fixed cells were rinsed twice with PBS and 
resuspended in propidium iodide solution (10 µg/mL) 
containing RNase A (100 µg/mL) in PBS. The stained cells 
were analyzed by a COULTER EPICS XLTM (Beckman 
Due to the extended π-conjugated system of molecular 
orbitals, C60 fullerene is able to generate toxic reactive 
oxygen species (ROS) in polar solvents after UV/Vis light 
absorption. Photoexcited C60 molecule is reduced from a 
long-lived triplet state (3C60
*) to radical anion C60
-• which 
subsequently reduces O2 to O2
-•; thereby initiating radical 
chain reactions with the generation of hydroxyl radical 
and hydrogen peroxide.9, 14 Photoexcited C60 fullerene or its 
derivatives have been shown to evoke oxidative stress and 
to induce apoptosis in cancer cells of different origins.14-18 
In this study, we used the photodynamic potential of 
C60 to enhance the cytotoxic effect of chemotherapeutic 
drug cisplatin towards murine leucosis cell line resistant 
to cisplatin. Cisplatin (cis-[Pt(NH3)2Cl2], Cis-Pt) belongs 
to the first-line highly efficient cytotoxic agents in current 
cancer therapy. It is generally accepted, in that the main 
Cis-Pt target is nuclear DNA, but recent studies have 
demonstrated that activation of apoptosis signaling 
pathways in the cytoplasm is the mechanism of Cis-Pt 
toxicity alternative to DNA damage.3, 19, 20 Therapeutic 
efficiencies of Cis-Pt are substantially limited by the 
development of cancer cells’ MDR. 
In the previous studies, we confirmed fullerene C60 
nanoparticles penetration into leukemic L1210 cells and 
demonstrated photoinduced cytotoxicity of accumulated 
C60 determined by ROS production.
21 The possibility to 
decrease substantially the viability of cisplatin-resistant 
L1210R cells by combined treatment with photoexcited 
C60 fullerene and cisplatin was also shown,
22 but the 
mechanisms of this phenomenon still need further 
investigation.
The aim of this study was to elucidate the possible 
molecular mechanism of photoexcited C60 fullerene-
dependent enhancement of cisplatin toxicity against 
leukemic cells resistant to cisplatin.
Materials and Methods
Materials
The materials used included: RPMI 1640 liquid medium 
(Sigma-Aldrich Co, Ltd, USA), fetal bovine serum (FBS) 
(Sigma-Aldrich Co, Ltd, USA), penicillin/streptomycin 
and L-glutamine (Merck KGaA (Darmstadt, Germany)), 
propidium iodide (Sigma-Aldrich Co, Ltd, USA), 
RNase A (Sigma, USA), tetramethylrhodamine ethyl 
ester perchlorate (TMRE) (Sigma, USA), antibodies 
against β-actin (1:2000 dilution) (Sigma, USA), anti-
phospho-p38 kinase antibodies (1:1000 dilution) (Cell 
Signaling, USA), DC Protein Assay kit (Bio-Rad, USA), 
cisplatin (cis-Pt, Sigma-Aldrich Co, Ltd, USA). 
Preparation and characterization of pristine C60  fullerene 
aqueous colloid solution
C60 fullerene aqueous colloid solution was synthesized 
and characterized in the Ilmenau Technical University 
(Germany) as described by Scharff et al.23 In brief, the 
toluene extract was obtained after graphite combustion 
Photoexcited C60 fullerene and cisplatin combination against drug-resistant L1210 cells
BioImpacts, 2019, 9(4), 211-217 213
Coulter, USA) and FCS Express 3 Flow Cytometry 
Software (DeNovo Software, USA).
Mitochondrial transmembrane potential assay
Mitochondrial membrane potential (Δψm) was estimated 
with the use of fluorescent potential-sensitive probe TMRE. 
Cells (107/mL) were suspended in buffer A containing 
(mM): KCl – 5, NaCl – 120, CaCl2 – 1, glucose – 10, MgCl2 
– 1, NaHCO3 – 4, HEPES – 10, pH 7.4, incubated with 
100 nM TMRE for 40 minutes at 25°C with the addition 
of 0.05% Pluronic F-127 and washed from the excess of 
probe. TMRE fluorescence was registered with Shimadzu 
RF-1501 spectrofluorometer (Japan), λexc=540 nm, 
λem=595 nm. Relative values of mitochondrial potential 
were determined as changes in probe fluorescence after 
the addition of protonophore FCCP (carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone) (1 μM).27
Statistics
The data were represented as Mean (M) ± standard 
deviation (SD) of more than four independent 
experiments. Mean and SD were calculated for each group. 
Statistical analysis was performed using two-way ANOVA 
followed by post Bonferroni test. A value of P < 0.05 was 
considered statistically significant. Data processing and 
plotting were performed by IBM PC using specialized 
applications GraphPad Prism 7 (GraphPad Software Inc., 
USA) and Gel-Pro Analyzer 6.3 (Media Cybernetics Inc., 
USA).
Results
Activation of p38 MAPK in L1210R cells after C60 
fullerene photoexcitation
Mitogen-activated p38 kinase (MAPK) is one of the 
important redox-sensitive and stress-activated targets 
involved in apoptosis induction by phosphorylation of 
proapoptotic proteins р53 and Вaх.28, 29 We examined p38 
MAPK activity in L1210R cells by estimation of the level of 
its active phosphorylated form (pp38) using Western blot 
analysis. As shown in Fig. 1, no statistically valid changes 
in the level of active p38 kinase were detected at 2-hour 
incubation of cells loaded with C60 fullerene or irradiated 
with 420-700 nm light alone, though photoexcitation of 
C60 fullerene accumulated with L1210R cells was followed 
by an increase of p38 MAPK level which was found to 
be 3 times higher than that in the control at 1 hour of 
incubation and remained at enhanced level at 2 hours.
This finding is in agreement with data presented by Li 
et al,30 where substantial activation of p38 MAP kinase 
was detected after light irradiation of MCF-7 cells loaded 
with C60 derivatives С60-phe or C60-gly. This increase was 
prevented by antioxidant N-acetyl-L-cystein and thus 
proved to be ROS dependent. Activation of p38 MAP 
kinase as a result of H2O2-induced oxidation of its thiol 
groups was also shown by Olson and Hallahan.29
A growing body of evidence suggests that p38 MAPK is able 
to control the p53-mediated response to several genotoxic 
stimuli and could be specific to cancer therapy.31, 32 The 
data on increase in the viability of HaCaT cells pretreated 
with p38 MAPK specific inhibitors before incubation with 
cisplatin as well as the data obtained in experimental head 
and neck cancer model indicating that lower activation 
or lack of activation of p38 MAPK correlates with a more 
resistant phenotype33 suggested that the inhibition of p38 
MAPK is a potential mechanism of resistance and that 
activation of this pathway could help to overcome cancer 
cells drug resistance. 
Interference into cell cycle transition is suggested to be 
one of the mechanisms of p38 MAP kinase involvement 
into apoptosis induction. To elucidate if ROS dependent 
effects of photoexcited C60 fullerene could disturb cell 
cycle checkpoints in cisplatin-resistant L1210R cells, we 
Fig. 1. Activation of p38 MAP kinase in L1210R cells treated with 10-5 M C60 fullerene and irradiated with 420-700 nm light: (A) Western blot 
analysis of pp38 MAPK level (typical blotogram); (B) quantitative analysis of the fold increase of pp38 MAPK level. (M±m, n=3); *Р<0.05 
in comparison to control.
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further studied the cells cycle distribution after combined 
treatment with photoexcited C60 and cisplatin. 
Cell cycle distribution of L1210R cells after the combined 
action of cisplatin and photoexcited C60 fullerene
Flow cytometric analysis showed that at 48 hour 
incubation of L1210R cells in control, the most significant 
content of cells (47.6±4.6%) was detected in the G0/G1 
phase (Figs. 2A, B). Accumulation of cisplatin-resistant 
cancer cells of different origins in the G0/G1 phase of 
cell cycle is believed to ensure the transition from G1 to S 
phase, DNA doubling, and mitosis.34, 35
No effect on cell cycle profile was detected after L1210R 
cells light irradiation (data not shown) or treatment with 
cisplatin alone, while treatment with C60 fullerene was 
followed by an increase of cells content in the subG1 phase 
(8.7±3.5% vs. 2.7±1.5% in control) (Figs. 2A, B). After 
C60 fullerene photoactivation, this effect was enhanced 
(14.4±2.9% vs. 2.7±1.5% in control) with simultaneous 
decrease of cells content in the G0/G1 phase. After 
combined treatment with photoexcited C60 fullerene and 
cisplatin, a decrease of cells content in the G2/M phase 
was shown, while the number of cells accumulated in 
subG1 phase was found to be substantially higher than 
that after C60 fullerene photoexcitation alone (28±4% vs. 
14.4±3% respectively) (Fig. 2B). Cells accumulation in 
the subG1 phase is considered to be the marker of the 
blockage of cell transition into S phase and transition to 
apoptotic pathway.8
Activation of proapoptotic MAP kinases in L1210R 
cells after C60 fullerene photoexcitation could be the initial 
step of the cell death program, but its realization needs 
reinforcement of apoptotic signals particularly at the 
level of mitochondria. Since acute apoptosis induced by 
cisplatin is shown to be associated with mitochondrial 
ROS response,20, 36 we tested whether combined treatment 
of L1210R cells with photoexcited C60 fullerene and 
cisplatin had an impact on mitochondrial redox status.
Mitochondrial membrane potential in L1210R cells after 
the combined action of cisplatin and photoexcited C60 
fullerene
The relative value of mitochondrial membrane potential 
(Δψm) in L1210R cells incubated for 2 hours after the 
treatment with either cisplatin or photoexcited C60 
fullerene alone or their combination was estimated with 
the use of fluorescent probe TMRE. 
No effect of light irradiation (data not shown) or 1 µg/
mL cisplatin alone on the Δψm value in L1210R cells was 
detected, while the tendency to its decrease after cells 
treatment with C60 fullerene was revealed (Fig. 3). 
C60 fullerene photoexcitation was followed by 1.7 fold 
decrease of Δψ relative value in L1210R cells as compared 
with control. Combined treatment with photoexcited C60 
fullerene and cisplatin was followed by further substantial 
decrease of TMRE fluorescent signal, the Δψ relative value 
was decreased 3.9 folds as compared with the control and 
2 folds as compared with the effect of photoexcited C60 
Fig. 2. Cell cycle distribution of L1210R cells at 48 hour time point after combined treatment with photoexcited C60 fullerene and cisplatin. 
(A) Representative histograms of a typical experiment. (B) % of total cell population in phases. (M±m, n=3); *Р<0.05 in comparison with 
control, #Р<0.05 in comparison with photoexcited С60 fullerene.
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fullerene alone, indicating the cisplatin involvement in 
mitochondria redox status disturbance. 
Discussion
The ability of photoexcited C60 fullerene to induce 
apoptosis in human leukemic cells was confirmed in our 
previous studies, where the depletion of mitochondrial 
Ca2+-pool, cytochrome c release from mitochondria to the 
cytosol, caspase - 3 activation and DNA fragmentation 
with the formation of the “ladder pattern” after UV/Vis 
irradiation (320-600nm) of cells treated with 10-5 M C60 
fullerene were demonstrated.37, 38
As we have shown earlier, the treatment of cisplatin 
resistant L1210R leukemic cells with cisplatin in a 
range of 0.1-10 µg/mL had no effect on cell viability, 
while substantial C60-mediated photodamaging effect 
was detected with 50% decrease of cell viability at 48 
hour time point after photoexcitation (420-700 nm) of 
accumulated carbon nanostructure.21 The intense ROS 
production detected at 3 hour time point after irradiation 
of L1210R cells loaded with C60 fullerene confirmed the 
ability of photoactivated C60 fullerene to generate O2
-• in 
intracellular space.22
In this study we demonstrated the activation of p38 MAP 
kinase in L1210R cells after treatment with C60 fullerene 
and light irradiation. These data indicate that p38 MAPK 
could be the target of ROS produced by photoexcited 
C60 and thus be involved in the molecular mechanisms 
of photoexcited C60 toxic effect against leukemic cells 
resistant to cisplatin. This suggestion was confirmed by 
the data indicating the ability of photoexcited C60 to evoke 
L1210R cells accumulation in proapoptotic subG1 phase 
of cell cycle. 
We showed that under combined treatment with 
photoexcited C60 and cisplatin in a low 1 μg/mL 
concentration, the synergic effect of both agents became 
apparent both in dropping the mitochondrial membrane 
potential and inducing L1210R cells accumulation in 
Fig. 3. Relative value of mitochondrial membrane potential in 
L1210R cells at 2 hour time point after combined treatment with 
photoexcited C60 fullerene and cisplatin. (M±m, n=5); *Р<0.05 in 
comparison with control, #Р<0.05 in comparison with photoexcited 
С60 fullerene.
subG1 phase of cell cycle. 
The synergic cytotoxic activity of photoexcited C60 and 
cisplatin could be realized on condition that cisplatin enters 
L1210R cells and is accumulated in intracellular space. The 
ability of C60 fullerene derivatives to reactivate cisplatin 
endocytosis in cancer cells and thus to circumvent tumor 
resistance to cisplatin8 as well as incapability of P-gp type 
of ABC transporters to recognize pristine C60 fullerene 
nanoparticles and to prevent their accumulation in drug-
resistant K562R leukemic cells7 confirm this assumption. 
Additionally, the expression of ABC family transporters 
responsible for drug efflux from cancer cells is shown to 
be ROS-regulated. Thus, ROS induced down-regulation 
of both P-glycoprotein in prostate tumor cells39 and MDR-
associated protein (MRP1) expression in urinary bladder 
cells40 were demonstrated. The results of our study allow 
suggesting that photoexcitation of C60 fullerene may 
affect the components of the system controlling cisplatin 
influx and accumulation in L1210R cancer cells, thereby 
promoting overcoming of drug resistance. 
Conclusion
Series of genetic and metabolic rearrangements allow 
cancer cells to prevent the cytotoxic effects of anticancer 
drugs. The phenomenon of cancer cells MDR substantially 
reduces the effect of anticancer therapy and the efficiency 
of cisplatin as the commonly used drug. In this respect, 
application of C60 fullerene nanoparticles seems to be 
perspective as they penetrate into cancer cells, avoid efflux 
by transporters of ABC family and facilitate drug delivery, 
produce toxic ROS after photoexcitation and enable 
combinatory treatment with anticancer drugs.
In this study the activation of p38 MAP kinase and the 
decrease of Δψm value as the inducing markers of ROS-
dependent apoptotic pathways in resistance to cisplatin 
leukemic L1210R cells treated with 10-5 M C60 fullerene 
What is the current knowledge?
√ C60 fullerene is potential for PDT and phenomenon of 
cancer cells MDR.
What is new here?
√ Activation of ROS-sensitive proapoptotic p38 kinase and 
enhanced content of cells in proapoptotic subG1 phase were 
detected when leukemic cell line L1210 resistant to Cis-Pt 
was treated with 10-5M C60 fullerene and irradiated with 
visible light.
√ Combined treatment of L1210R cells with photoexcited 
C60 fullerene and Cis-Pt in low concentration was followed 
by the intensification of proapoptotic effects. 
√ The effect of the synergic cytotoxic activity of both agents 
allowed us to suppose that photoexcited C60 fullerene 
promoted Cis-Pt accumulation in leukemic cells resistant to 
Cis-Pt.
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and irradiated with visible light was shown. The data 
obtained indicated that combined treatment of L1210R 
cells with photoexcited C60 fullerene and cisplatin in a low 
1 µg/mL dose was followed by more intense proapoptotic 
effect as compared with treatment with photoexcited C60 
fullerene alone. Dissipation of Δψm at early term period, 
the blockage of cell transition into S phase and mitosis 
with accumulation in the proapoptotic subG1 phase of the 
cell cycle at long-term period after combined treatment 
of L1210R cells were detected. The effect of synergic 
cytotoxic activity allowed us to suppose that photoexcited 
C60 fullerene promoted cisplatin accumulation in 
L1210R cells. The data obtained could be useful for the 
development of approaches to overcome drug-resistance 
of leukemic cells and to extend the methods of PDT.
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